Valuation: Brooks Laboratories Limited

Market Cap 1.09B 11.45M 9.95M 9.27M 8.51M 16.06M 16.31M 109M 42.86M 544M 43.01M 42.06M 1.82B P/E 2024
-12.2x
P/E 2025 -28.6x
Enterprise Value 1.17B 12.24M 10.64M 9.9M 9.09M 17.17M 17.44M 117M 45.82M 582M 45.97M 44.96M 1.95B EV / Sales 2024
3.16x
EV / Sales 2025 3.93x
Free-Float
44.12%
Yield 2024 *
-
Yield 2025 -
07-17 Brooks Laboratories Limited Announces Appointment of Rajesh Mahajan to President Trading and Senior Management Personnel, Effective July 17, 2026 CI
06-18 Steriscience Specialties Private Limited agreed to acquire an additional 16.33% stake in Brooks Steriscience Limited from Brooks Laboratories Limited for INR 1.1 billion. CI
05-29 Brooks Laboratories appoints Prashant Rathi as CEO RE
05-29 Brooks Laboratories names Prashant Rathi as CEO RE
05-29 Brooks Laboratories Limited Announces Appointment of Prashant Rathi as Chief Executive Officer, Effective June 1, 2026 CI
05-29 Brooks Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2026 CI
02-06 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
25-10-16 Brooks Laboratories Limited Announces That Mr. Rajesh Mahajan Resigned as President - Procurement, with Effect from 16 October 2025 CI
25-08-13 Brooks Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2025 CI
25-05-28 Brooks Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2025 CI
25-02-13 Brooks Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2024 CI
24-12-26 Brooks Laboratories Limited Appoints Ms. Krutika Mohan Rane as Company Secretary & Compliance Officer, Effective 26 December 2024 CI
24-12-10 Brooks Laboratories Limited announced that it expects to receive INR 750 million in funding from Jalan Chemical Industries Private Limited, K M Visaria Family Trust CI
1 day+3.72%
1 week-4.98%
1 month-11.53%
3 months+8.00%
6 months-1.28%
Current year-23.99%
1 week 58.16
Extreme 58.16
65.95
1 month 58.16
Extreme 58.16
79
Current year 36.9
Extreme 36.9
82.3
1 year 36.9
Extreme 36.9
165.95
3 years 36.9
Extreme 36.9
202.8
5 years 36.9
Extreme 36.9
202.8
10 years 14.05
Extreme 14.05
202.8
Manager TitleAgeSince
Chief Executive Officer 58 2002-01-22
Chief Executive Officer - 2026-05-31
President 57 2023-08-22
Director TitleAgeSince
Director/Board Member 53 2022-11-22
Director/Board Member 62 2010-09-09
Director/Board Member - 2023-08-22
Change 5-day change 1-year change 3-year change Capi.($)
+3.72%-4.98% - - 18.82M
-0.53%+2.54%+16.63%+74.09% 50.03B
-1.81%-0.49%+51.99%+112.44% 36.6B
+0.46%+4.44%-5.24%+25.38% 12.47B
+1.05%+1.63%+16.19%+78.22% 11.77B
-1.33%-0.76%+30.08%+131.70% 9.04B
-2.99%-2.09%+41.02%-8.36% 7.03B
+0.51%+1.46%+12.17%+32.88% 6.79B
-.--%+0.14% - - 6.79B
+1.99%+1.91%+4.68%+183.54% 6.6B
Average +0.11%+1.00%+20.94%+78.74% 16.35B
Weighted average by Cap. -0.62%+1.27%+25.18%+82.84%

Financials

2024 2025
Net sales 795M 8.33M 7.24M 6.74M 6.19M 11.68M 11.86M 79.42M 31.17M 396M 31.27M 30.58M 1.33B 826M 8.65M 7.52M 7M 6.42M 12.13M 12.32M 82.48M 32.37M 411M 32.48M 31.77M 1.38B
Net income -196M -2.05M -1.78M -1.66M -1.52M -2.88M -2.92M -19.57M -7.68M -97.54M -7.71M -7.54M -327M -99.67M -1.04M -908K -845K -776K -1.46M -1.49M -9.96M -3.91M -49.62M -3.92M -3.84M -166M
Net Debt 55.16M 578K 502K 468K 429K 811K 823K 5.51M 2.16M 27.46M 2.17M 2.12M 92.09M 75.39M 790K 687K 639K 587K 1.11M 1.13M 7.53M 2.96M 37.53M 2.97M 2.9M 126M
Logo Brooks Laboratories Limited
Brooks Laboratories Limited is an India-based pharmaceutical manufacturing company working on a contract basis. The Company’s segment is Pharmaceutical products, including ingredients and intermediaries. It manufactures various pharmaceutical dosage forms, including injections, tablets, dry syrup, and eye/ear drops. Its products under the Carbapenem category are Imipenem 250 (Milligram) mg + Cilastatin 250mg, Imipenem 500mg + Cilastatin 500mg, Meropenem 250mg, Meropenem 500mg, Meropenem 1000mg+Sulbactam 500mg, Meropenem 1000mg+Tazobactam 500mg, and Doripenem 500mg. It offers Penicillins in the form of injections, tablets, and dry syrup. Its general category of products includes liquid injections, dry powder injections and eye/ear drops. Its liquid injections include Iron sucrose 100mg/5ml, Iron sucrose 50mg/2.5ml, Phenytoin sodium 50mg/ml and others. Its dry powder injections include Artesunate 60mg, Artesunate 120mg, Omeprazole 40mg, Rabeprazole 20mg, Pantoprazole 40mg and others.
Employees
323
Date Price Change Volume
26-07-31 ₹61.00 +3.72% 1,739
26-07-30 ₹58.81 -2.13% 2,275
26-07-29 ₹60.09 -4.10% 2,355
26-07-28 ₹62.66 -4.99% 1,253
26-07-27 ₹65.95 +2.73% 269